The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.

The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor. Ann Endocrinol (Paris). 2020 Aug 18;: Authors: Feng X, Qingwei G, Gao G, Yuan L, Li Q, Zhang Y Abstract PURPOSE: The aim of this study was to determine the levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) after treatment with an SGLT2 inhibitor or DPP4 inhibitor in patients with type 2 diabetes mellitus that was inadequately controlled with insulin and to understand whether the variation of ANP may explain the favorable cardiovascular outcome. METHODS: We enrolled 56 patients with type 2 diabetes mellitus that was inadequately controlled with insulin; the subjects were all 18∼80 years of age. After receiving a stable mean dose of ≥ 20 IU and ≤ 150 IU injectable insulin daily combined with or without no more than two oral antidiabetic agents for at least 8 weeks, patients who still experienced inadequate glycaemic control (HbA1c levels of 7.5∼10.5 %) were recruited. FINDINGS: A total of 56 patients were enrolled in this study and randomized into three groups, including an SGLT2 inhibitor group (n=18), a DPP4 inhibitor group (n=19) and a placebo group (n=19). Patients who received SGLT2 inhibitor or DPP4 inhibitor treatment all had significantly decreased HbA1c levels, fasting blood glucose (FBG) levels and systolic blood pressure at...
Source: Annales d'Endocrinologie - Category: Endocrinology Authors: Tags: Ann Endocrinol (Paris) Source Type: research